Title of article
Continuing Evolution of Multidisciplinary Approach to Prevention of Central Line–Associated Bacteremias
Author/Authors
Loretta L. Fauerbach، نويسنده , , C. Ruse، نويسنده , , M. A. Gross، نويسنده , , R. Kelly، نويسنده , , D. Danek، نويسنده , , L. Larson، نويسنده , , J. Janelle، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2004
Pages
2
From page
40
To page
41
Abstract
Continuing Evolution of Multidisciplinary Approach to Prevention of Central Line–Associated Bacteremias
Pages E40-E41
L. L. Fauerbach*, C. Ruse, M. A. Gross, R. Kelly, D. Danek, L. Larson, J. Janelle
Close Close preview | Purchase PDF (63 K) | Related articles | Related reference work articles
AbstractAbstract
Abstract
ISSUE: Prevention of central line–associated bacteremias (BSIc) is a major focus for our 570-bed tertiary/transplant center. Historical risk-reduction strategies include: use of antimicrobial impregnated CVL, CVL insertion tray designed to facilitate total barrier technique compliance, and use of 0.5% chlorhexidine gluconate and 70% alcohol solution (0.5% CHG) for site prep. Our rates increased following market removal of 0.5% CHG. When new 2 % CHG skin prep solution (2% CHG and 70% alcohol) and a CHG–impregnated patch became available, studies to determine impact of these new products were initiated.
PROJECT: BSIc surveillance was performed by infection control professionals according to CDC definitions and reported quarterly. Initially, CVL utilization was 151 patients/per day had at least one CVL. Staff was educated about each new product prior to implementation. The skin prep was first changed to 2% CHG. Subsequently, CHG–impregnated patch was introduced.
RESULTS: During the study, CVL utilization increased to 220 patients/day with a CVL. Introduction of 2% CHG prep plus the CHG patch resulted in an overall 31% reduction in BSIc, of which a 16% reduction was attributable to the CHG patch. This reduction resulted in averting 135 infections and cost aversion of $2.5 million.
LESSONS LEARNED: Implementing new technologies for reducing BSIc must be an ongoing process. The use of 2% CHG skin prep and a CHG-impregnated patch significantly reduced BSIc in our setting. Evaluation and comparison to hospital-specific baseline data is important to determine the impact of the changes on patient safety and cost management.
Journal title
American Journal of Infection Control (AJIC)
Serial Year
2004
Journal title
American Journal of Infection Control (AJIC)
Record number
635750
Link To Document